Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer

ABSTRACT: Interventions: Oral S-1, leucovorin plus bevacizumab therapy Primary outcome(s): Disease control rate assessed by independent review committee Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2624484 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR